New plan could shake up pricing and HTA process in Australia

Medicines Australia, the leading trade group for the biotech and pharma industries in the country, has helped negotiate a five-year strategic plan with the national government.

Focused on boosting the availability of innovative medicines, the new agreement is said by the group to secure “stronger patient involvement in critical processes,” while enabling Australia to “keep pace with access to rapidly transforming medical advancements developed around the world.”

The strategy also provides for more funding to be invested into the all-important Pharmaceutical Benefits Scheme (PBS), adding to around A$3 billion ($2.2 billion) already announced.